ISRCTN99414122

October 2006 Issue 32

Headlines:

- Main phase
- New staff
- Investigator Meetings
- Tip of the month

Current Recruitment 522

Congratulations to
Dunedin, New
Zealand for
randomising their first
patient!



ENOS Trial Office

enos@nottingham.ac.uk
Tel +44 115 823 1770
Fax.+44 115 823 1771

Chief Investigator
Philip Bath
+44 115 823 1768

Trial Medic Gillian Sare +44 115 823 1769

Trial Manager
Sally Utton
+44 115 823 0287

Trial Statistician
Laura Gray
+44 115 823 1772

CT Coordinator Lida Kaur +44 115823 1776

Research Secretary Yvonne Smallwood +44 115 823 1770

ENOS NEWS



The Newsletter for the 'Efficacy of Nitric Oxide in Stroke' Trial

Main phase

The main phase of the ENOS trial begins on 1 November 2006, funded by MRC and we are seeking new centres. Updated paperwork will be forthcoming for the main phase of the trial, including new contracts, updated protocol and patient information sheets.

New staff

The ENOS Trial Office is undergoing an expansion of staff and recently joined are Dr Gillian Sare, Trial Medic, Sally Utton, Trial Manager and Yvonne Smallwood, Research Secretary.

Investigator Meetings

Thank you to all investigators who joined us at the ENOS meeting at the Joint World Stroke Congress in Cape Town, South Africa, on 28 October.

We would like to invite any investigators travelling to the UK Stroke Forum Conference in Harrogate 6-8 December to join us for an informal investigators meeting. We will meet at 6pm on Thursday 7 December (gala dinner at 7.30pm) at the Wetherspoon's bar on Parliament Street. This will be a great opportunity for us to meet again and discuss any issues with the trial, and to welcome any new investigators. We look forward to seeing you there.

Tip of the month

A common question is whether patients with known significant ipsilateral carotid stenosis can, or should be, enrolled in the trial. We presented data from ENOS on this, at last weeks Joint World Stroke Congress in Cape Town. To date, no early recurrences have occurred in the 34 patients with significant ipsilateral carotid stenosis, irrespective of the group they were randomised to. So, we welcome such patients being enrolled into ENOS. The Data Monitoring Committee are also regularly assessing this issue.